Viridian Therapeutics, Inc.\DE (VRDN) Change in Account Payables (2016 - 2026)

Viridian Therapeutics, Inc.\DE's Change in Account Payables history runs 11 years deep, the most recent figure standing at $4.6 million for Q1 2026.

• In Q1 2026, Change in Account Payables rose 162.32% year-over-year to $4.6 million; the TTM figure through Mar 2026 stood at $9.4 million (up 679.09% YoY), while the FY2025 annual figure was $6.6 million, up 9089.04% from the prior year.
• Change in Account Payables for Q1 2026 stood at $4.6 million, up from -$1.4 million in the prior quarter.
• The five-year high for Change in Account Payables was $8.0 million in Q3 2022, with the low at -$6.6 million in Q1 2023.
• The 5-year median for Change in Account Payables is $482000.0 (2024), against an average of $623705.9.
• The sharpest annual moves came in 2023 and 2024: Change in Account Payables plunged 21541.94% in 2023, then jumped 2812.96% in 2024.
• Viridian Therapeutics, Inc.\DE's Change in Account Payables stood at $1.7 million in 2022, then plunged by 186.88% to -$1.5 million in 2023, then plunged by 158.77% to -$3.9 million in 2024, then soared by 64.82% to -$1.4 million in 2025, then soared by 435.51% to $4.6 million in 2026.
• Business Quant data shows VRDN's Change in Account Payables at $4.6 million in Q1 2026, -$1.4 million in Q4 2025, and $1.5 million in Q3 2025.